# Filing Detail

Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-003848
Filing Date
2025-04-11
Accepted
2025-04-11 16:30:35
Documents
23
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formpre14a.htm iXBRL | PRE 14A | 678110
2 |  | formpre14a_001.jpg | GRAPHIC | 10758
3 |  | formpre14a_002.jpg | GRAPHIC | 10758
4 |  | formpre14a_003.jpg | GRAPHIC | 58474
5 |  | formpre14a_004.jpg | GRAPHIC | 55200
6 |  | formpre14a_005.jpg | GRAPHIC | 286421
7 |  | formpre14a_006.jpg | GRAPHIC | 198187
| Complete submission text file | 0001641172-25-003848.txt |  | 2986918

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL SCHEMA FILE | tnfa-20241231.xsd | EX-101.SCH | 6529
9 | XBRL DEFINITION FILE | tnfa-20241231_def.xml | EX-101.DEF | 11755
10 | XBRL LABEL FILE | tnfa-20241231_lab.xml | EX-101.LAB | 67780
11 | XBRL PRESENTATION FILE | tnfa-20241231_pre.xml | EX-101.PRE | 44371
25 | EXTRACTED XBRL INSTANCE DOCUMENT | formpre14a_htm.xml | XML | 147222

Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36268 | Film No.: 25832484
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)